| Full text | |
| Author(s): |
Chiba, Camila Hiromi
[1]
;
Knirsch, Marcos Camargo
[1]
;
Azzoni, Adriano Rodrigues
[2]
;
Moreira, Antonio R.
[3]
;
Stephano, Marco Antonio
[1]
Total Authors: 5
|
| Affiliation: | [1] Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Tecnol Bioquim Farmaceut, Sao Paulo - Brazil
[2] Univ Sao Paulo, Escola Politecn, Dept Engn Quim, Sao Paulo - Brazil
[3] Univ Maryland Baltimore Cty, Dept Chem Biochem & Environm Engn, Baltimore, MD 21228 - USA
Total Affiliations: 3
|
| Document type: | Review article |
| Source: | BIOTECHNIQUES; v. 70, n. 2 JAN 2021. |
| Web of Science Citations: | 0 |
| Abstract | |
Biopharmaceutical products are of great importance in the treatment or prevention of many diseases and represent a growing share of the global pharmaceutical market. The usual technology for protein synthesis (cell-based expression) faces certain obstacles, especially with `difficult-to-express' proteins. Cell-free protein synthesis (CFPS) can overcome the main bottlenecks of cell-based expression. This review aims to present recent advances in the production process of biologic products by CFPS. First, key aspects of CFPS systems are summarized. A description of several biologic products that have been successfully produced using the CFPS system is provided. Finally, the CFPS system's ability to scale up and scale down, its main limitations and its application for biologics production are discussed. (AU) | |
| FAPESP's process: | 18/15794-6 - Production of recombinant interferon beta 1b protein at plataform cell-free protein synthesis |
| Grantee: | Marco Antonio Stephano |
| Support Opportunities: | Regular Research Grants |